ÂÜÀòÂÒÂ×

Rupert Kenefeck is a seasoned professional in the field of translational medicine, currently serving as Senior Director of Translational Medicine at Quell Therapeutics since March 2024. Previously, Rupert held the position of Head of Translational Medicine at Evox Therapeutics Ltd from August 2022 to March 2024, and served as Director and Associate Director of Translational Platforms at Molecular Partners from June 2020 to August 2022. Rupert's career also includes significant roles at Immunocore Limited as Group Leader and Senior Scientist, and postdoctoral research fellowships at University College London and the University of Birmingham. Rupert earned a PhD in Immunology from the University of Nottingham and a degree in Medical Microbiology and Immunology from the University of Newcastle-upon-Tyne.